ANDA 216624, held by Accord Healthcare. Naloxone Hydrochloride.
As of Nov 22, 2026, ANDA 216624 (Naloxone Hydrochloride), held by Accord Healthcare, was first approved by FDA on Oct 26, 2022, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 26, 2022 | Original application | Approved | None posted |
| Naloxone Hydrochloride0.4MG/ML · injectable;injection | Naloxone Hydrochloride | Rx |
| Naloxone Hydrochloride1MG/ML · injectable;injection | Naloxone Hydrochloride | Rx |
| Jun 26, 2025 | Supplement 4Manufacturing | Approved | None posted |
| May 15, 2023 | Supplement 1Labeling · Standard review | Approved | None posted |
| Oct 26, 2022 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters